Australia Stock Exchange release from INVION : Complete Regression of TNBC Tumours and Protective Immunity
27/10/2021 23:43
Australia Stock Exchange release from INVION IVX.AX : Complete Regression of TNBC Tumours and Protective Immunity
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation